These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

951 related items for PubMed ID: 16152754

  • 1. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C, Soriano V, Pérez-Olmeda M, Rodríguez-Rosado R, González-Lahoz J.
    J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S.
    J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230
    [Abstract] [Full Text] [Related]

  • 4. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 5. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [Abstract] [Full Text] [Related]

  • 6. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.
    Clin Infect Dis; 2008 Feb 15; 46(4):611-21. PubMed ID: 18197758
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Feb 15; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
    Duvivier C, Myrto A, Marcelin AG, Ghosn J, Ait-Mohand H, Schneider L, Agher R, Bricaire F, Costagliola D, Calvez V, Peytavin G, Katlama C.
    Antivir Ther; 2003 Dec 15; 8(6):603-9. PubMed ID: 14760894
    [Abstract] [Full Text] [Related]

  • 9. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Dec 15; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 10. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F, VIRGO Study Team.
    Antivir Ther; 1999 Dec 15; 4 Suppl 3():83-4. PubMed ID: 16021876
    [Abstract] [Full Text] [Related]

  • 11. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
    Pérez H, Vignoles M, Laufer N, Gómez A, Coll P, Lottner J, Rolón M, Salomón H, Cahn P.
    Antivir Ther; 2008 Dec 15; 13(1):135-9. PubMed ID: 18389908
    [Abstract] [Full Text] [Related]

  • 12. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F, Reliquet V, Francois C, Garre M, Hascoet C, Allavena C, Arvieux C, Breux JP, Perre P, Rozenbaum W, Auger S.
    Antivir Ther; 1998 Dec 15; 3 Suppl 4():57-60. PubMed ID: 10723512
    [Abstract] [Full Text] [Related]

  • 13. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct 15; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

  • 14. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Raffi F, Reliquet V, Ferré V, Arvieux C, Hascoet C, Bellein V, Besnier JM, Breux JP, Garré M, May T, Molina JM, Perré P, Raguin G, Rozenbaum W, Zucman D.
    Antivir Ther; 2000 Dec 15; 5(4):267-72. PubMed ID: 11142621
    [Abstract] [Full Text] [Related]

  • 15. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 16. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J.
    Antivir Ther; 2002 Jun 10; 7(2):81-90. PubMed ID: 12212928
    [Abstract] [Full Text] [Related]

  • 17. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov 10; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 18. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
    Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L, Liégeois F, Andrieux-Meyer I, Zekeng L, Calmy A, Mpoudi-Ngolé E, Delaporte E.
    Antivir Ther; 2005 Nov 10; 10(2):335-41. PubMed ID: 15865228
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of a didanosin-containing regimen including genotypic resistance testing: an open-label, multicenter study.
    Treichel S, Hartmann M, Rump A, Brust J, Schuster D, Mosthaf F, Procaccianti M, Klinker H, Petzoldt D.
    Eur J Med Res; 2003 Sep 29; 8(9):405-13. PubMed ID: 14555296
    [Abstract] [Full Text] [Related]

  • 20. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.
    Maggiolo F, Migliorino M, Maserati R, Pan A, Rizzi M, Provettoni G, Rizzi L, Suter F, Once Study Group.
    Antivir Ther; 2001 Dec 29; 6(4):249-53. PubMed ID: 11878406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.